The global fluorescence in situ hybridization imaging systems market size was estimated at USD 704.5 million in 2016 and is anticipated to grow at a CAGR of 8.1% over the forecast period. The growing prevalence of target diseases leads to clinical urgency for the adoption of rapid diagnostic alternatives such as Fluorescence In Situ Hybridization (FISH) imaging systems, which is anticipated to fuel demand in the coming years. In addition, rising awareness about the associated benefits of this system, such as rapid analysis, enhanced visualization, high precision of results, and a wide range of application, is also among the major factors responsible for increased adoption.
The market is also predominantly driven by technologically advanced products in the field of in-vitro diagnostics. For instance, the advent of 3D FISH technology is one of the major advancements responsible for increased demand for FISH imaging systems. It facilitates three-dimensional visualization and analysis of target cells, thereby improving the potential for positive research outcomes. Positive research outcomes, reduced procedural time, ease of usage, and greater probe labeling efficiency are some of the benefits associated with the use of FISH imaging, and this is also expected to boost demand.
Moreover, a combination of FISH imaging equipment with other advanced technologies, such as high-throughput automated imaging systems & software, which yields faster, more efficient, and clear results, is expected to accelerate growth over the coming years. This is also anticipated to create new avenues for research applications.
For instance, research applications of FISH imaging systems have facilitated viewing of complex genomic structures and revealed their respective functions in various biological processes. This upgrade will facilitate real-time analysis of fluctuations in disease progression. These factors are expected to boost industry growth in the coming years.
In 2016, instruments held the dominant share because of greater adoption owing to benefits offered by imaging systems such as microscopes, spectrophotometers, and others. In addition, services are expected to grow exponentially during the forecast period owing to their increased adoption due to higher cost-efficiency.
The services segment is anticipated to witness lucrative CAGR during the forecast period owing to the need for a more complex and multilayered drug development system. FISH imaging services are likely to be essential in this system due to the formulation of new combinations and therapies that require higher precision.
Industry players are developing a range of services to simplify the overall process. These services are expected to result in a reduction of overall expenditure due to which they are likely to be preferred by researchers and scientists. The lucrative growth of this segment can also be attributed to increasing outsourcing to improve operations and ensure high adherence to quality standards.
Other benefits include cost advantages, increased efficiency of services, enhanced productivity, and a higher focus on core areas of development, which are critical to a company's growth. According to an NCBI survey, outsourcing results in cost savings of up to 60% and ensures better quality. In addition, contract services eliminate the need for infrastructure, which leads to significant cost reduction.
Cancer diagnostics accounted for a substantial share in the application segment. This can be attributed to the growing prevalence of diseases, such as cancer and genetic abnormalities. In addition, the high demand for accurate, sensitive, and rapid diagnosis of cancer is expected to lead to the growth of this segment.
Moreover, a growing number of research initiatives by major players for the development of advanced systems is expected to increase the scope for growth. This is anticipated to further boost the adoption of cancer diagnostics during the forecast period.
On the other hand, genetic diseases are expected to witness growth at a lucrative CAGR during the forecast period. Technological advancements are expected to lead to the exponential growth of this segment over the coming years.
An increase in the incidence of rare diseases caused by genetic aberrations is a high impact rendering driver for genetic disease testing. According to data published in NCBI, 80% of rare diseases are caused by genetic abnormalities.
In 2016, diagnostic laboratories accounted for the largest share in the end-use segment, as this technique is used for the detection of leukemia, myelodysplastic syndrome, multiple myeloma, and chromosomal abnormalities. On the other hand, an increasing number of research initiatives for cell research is expected to fuel growth.
The clinical diagnostics segment held a dominant share, and this can be attributed to the adoption of this technique in a wide range of applications, such as diagnosis of cancer, infectious diseases, genetic disorders, and others. The major benefits of these systems, including high speed for conducting assays, have made them one of the key cytogenetic diagnostic procedures.
The high prevalence of breast cancer is one of the major factors responsible for fueling the adoption of this technique for clinical purposes. It is the second-largest cause of cancer-related deaths and a major contributor to world mortality rates. According to the American Cancer Society, in 2017, around 252,710 new cases of breast cancer are expected to be diagnosed globally and this number is anticipated to grow over the coming years.
These systems possess the ability to automatically quantify various parameters, such as the stage of the disease and cell viability, as compared to conventional cytogenetics. These benefits are expected to drive the fluorescence in situ hybridization imaging systems market over the forecast period. In addition, technological advancements such as integration with a lab-on-a-chip microfluidic device are anticipated to propel the growth.
In 2016, North America held a dominant share of the industry. Key players are entering into collaborations to expand their product portfolios and improve their revenue share, which is a major factor contributing to growth across this region. The major share held by this region can also be attributed to extensive research & new product developments by major players.
The Asia Pacific region is expected to exhibit exponential growth during the forecast period. This can be attributed to growing healthcare spending and awareness among researchers and pathologists about the benefits of this technique in diagnostics. In addition, some of the prominent market players are consistently promoting the adoption of these systems through various initiatives, and this is also expected to propel demand in the region.
Growing awareness in emerging economies, such as India and China, coupled with extensive economic development in these countries is also anticipated to create significant growth opportunities in this market.
Key players are extensively implementing strategies to sustain their position in a competitive environment. Some of the prominent players are Leica BiosystemsNussloch GmbH; Thermo Fisher Scientific, Inc.; and PerkinElmer, Inc. Their strategies include mergers & acquisitions, distribution agreements, development of new products, and geographical expansion.
For instance, in May 2017, Leica Biosystems entered into a partnership with W.L.L.-a technical services supplies trading & contracting company-that is the distributor of the Kuwait Ministry of Health. Through this partnership, The Pathology Council of Kuwait will use the company’s digital pathology system as its standard care delivery product.
Prominent market players are employing various strategies to curb rising operational costs, thereby broadening their prospects for profitability. In addition, these companies are strengthening their supply chain, refining operational structures, and are opting for distributor-to-direct conversions. Furthermore, market players are consistently adding new products to their existing line of diagnostic products to maintain their competitive edge, thus contributing to market growth.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, Brazil, Mexico, South Africa, Saudi Arabia
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels, and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global fluorescence in situ hybridization imaging systems market on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Automated cell analyzers
Consumables & Accessories
Application Outlook (Revenue, USD Million, 2014 - 2025)
Genetic Disease Diagnosis
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Research & Academic Institutes
Regional Outlook (Revenue, USD Million, 2014 - 2025)
The Middle East & Africa
b. The global fluorescence in situ hybridization imaging systems market size was estimated at USD 885.9 million in 2019 and is expected to reach USD 957.0 million in 2020.
b. The global fluorescence in situ hybridization imaging systems market is expected to grow at a compound annual growth rate of 8.1 % from 2017 to 2025 to reach USD 1.41 billion by 2025.
b. North America dominated the fluorescence in situ hybridization imaging systems market with a share of 45.2% in 2019. This is attributable to the presence of major market players and extensive research & new product developments by these players.
b. Some key players operating in the fluorescence in situ hybridization imaging systems market include Leica BiosystemsNussloch GmbH; Thermo Fisher Scientific, Inc.; and PerkinElmer, Inc.
b. Key factors that are driving the market growth include the Growing prevalence of target diseases and rising awareness about the associated benefits of this system, such as rapid analysis, enhanced visualization, high precision of results, and a wide range of applications.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.